Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 window study of amcenestrant versus letrozole in pre-operative ER+ HER2- breast cancer
jRCT2031200169Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jan 2021
- Modality
- Small Molecules
01
Overview
Phase 2, randomised trial of amcenestrant in breast cancer (3 arms), sponsored by Sanofi. Primary endpoint: Change in Ki67. Started Jan 2021; status: completed.
02
Drugs
amcenestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031200169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200169.